The change is a way to almost directly compare to the lecanamab results, but in itself says nothing about how confident Anavex are in beating Eisai/Biogen at their own game.
We could speculate that, hopefully very clearly, the Anavex P2b/3 results demonstrates that A2-73 is at least as good as lecanamab with the safety profile and oral administration as a big advantage.
Market Data 
Markets 
AI
